Interleukin-33 as a Potential Therapeutic Target in Gastric Cancer Patients: Current Insights
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin-33 as a Potential Therapeutic Target in Gastric Cancer Patients: Current Insights
Authors
Keywords
-
Journal
OncoTargets and Therapy
Volume Volume 16, Issue -, Pages 675-687
Publisher
Informa UK Limited
Online
2023-08-10
DOI
10.2147/ott.s389120
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mitochondrial GRIM-19 loss in parietal cells promotes spasmolytic polypeptide-expressing metaplasia through NLR family pyrin domain-containing 3 (NLRP3)-mediated IL-33 activation via a reactive oxygen species (ROS) -NRF2- Heme oxygenase-1(HO-1)–NF–кB axis
- (2023) Xin Zeng et al. FREE RADICAL BIOLOGY AND MEDICINE
- Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression
- (2023) Yipin Lv et al. Journal of Advanced Research
- Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- (2022) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- IL-33 promotes gastric tumour growth in concert with activation and recruitment of inflammatory myeloid cells
- (2022) Chau P. Tran et al. Oncotarget
- Clinical implications of interleukins-31, 32, and 33 in gastric cancer
- (2022) Qing-Hua Liu et al. World Journal of Gastrointestinal Oncology
- A synergistic partnership between IL-33/ST2 and Wnt pathway through Bcl-xL drives gastric cancer stemness and metastasis
- (2022) Jong-Wan Kwon et al. ONCOGENE
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- IL‑33/ST2 promotes the malignant progression of gastric cancer via the MAPK pathway
- (2021) Ning Huang et al. Molecular Medicine Reports
- Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma
- (2021) Casey J. Allen et al. ANNALS OF SURGERY
- WFDC2 Promotes Spasmolytic Polypeptide-Expressing Metaplasia Through the Up-Regulation of IL33 in Response to Injury
- (2021) Haengdueng Jeong et al. GASTROENTEROLOGY
- Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review
- (2021) Sheng-Xiong Zhang et al. Recent Patents on Anti-Cancer Drug Discovery
- The long noncoding RNA noncoding RNA activated by DNA damage (NORAD)-microRNA-496-Interleukin-33 axis affects carcinoma-associated fibroblasts-mediated gastric cancer development
- (2021) Chaoqun Huang et al. Bioengineered
- Targeted Therapies in Advanced Gastric Cancer
- (2020) Timil H. Patel et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- IL-33 triggers early eosinophil-dependent events leading to metaplasia in a chronic model of gastritis-prone mice
- (2020) Carlo De Salvo et al. GASTROENTEROLOGY
- IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization
- (2019) Moritz F. Eissmann et al. Nature Communications
- The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-α/IL-33/ST2L signaling promotes gastric cancer metastasis
- (2019) Quan Zhou et al. ONCOGENE
- Helicobacter pylori Induces IL-33 Production and Recruits ST-2 to Lipid Rafts to Exacerbate Inflammation
- (2019) Kuo et al. Cells
- Staging and surgical approaches in gastric cancer: A systematic review
- (2018) Natalie Coburn et al. CANCER TREATMENT REVIEWS
- Role of the IL-33/ST2L axis in colorectal cancer progression
- (2018) Miho Akimoto et al. CELLULAR IMMUNOLOGY
- Injury, repair, inflammation and metaplasia in the stomach
- (2018) Anne R. Meyer et al. JOURNAL OF PHYSIOLOGY-LONDON
- Interleukin-33 enhanced the migration and invasiveness of human lung cancer cells
- (2018) Zhiping Yang et al. OncoTargets and Therapy
- Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ–Dependent Manner
- (2018) Moritz F. Eissmann et al. Cancer Immunology Research
- The Role of IL-33/ST2 Pathway in Tumorigenesis
- (2018) Kristen Larsen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity
- (2018) Claudia Afferni et al. Frontiers in Immunology
- A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach
- (2017) Christine P Petersen et al. GUT
- Wounds that heal and wounds that don’t − The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis
- (2017) Neal L. Millar et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Progress in the treatment of advanced gastric cancer
- (2017) Zheyu Song et al. TUMOR BIOLOGY
- Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
- (2017) Yelena Y. Janjigian et al. Cancer Discovery
- Serum IL-33 level is a predictor of progression-free survival after chemotherapy
- (2017) Wenwei Hu et al. Oncotarget
- IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model
- (2017) Kailing Wang et al. Oncotarget
- IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils
- (2017) Valeria Lucarini et al. OncoImmunology
- Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc Min/+ mice
- (2017) Zhengxiang He et al. Scientific Reports
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- IL-33 signaling fuels outgrowth and metastasis of human lung cancer
- (2016) Chunhong Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- High plasma sST2 levels in gastric cancer and their association with metastatic disease
- (2016) Dominik Bergis et al. Cancer Biomarkers
- Interleukin-33, friend and foe in type-2 immune responses
- (2016) Clare Hardman et al. CURRENT OPINION IN IMMUNOLOGY
- IL-33 regulates the IgA-microbiota axis to restrain IL-1α–dependent colitis and tumorigenesis
- (2016) Ankit Malik et al. JOURNAL OF CLINICAL INVESTIGATION
- Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer
- (2016) Donye Dominguez et al. JOURNAL OF IMMUNOLOGY
- Intratumorally Establishing Type 2 Innate Lymphoid Cells Blocks Tumor Growth
- (2016) Juyang Kim et al. JOURNAL OF IMMUNOLOGY
- Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy
- (2016) Binfeng Lu et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis
- (2016) Yu Zhang et al. MOLECULAR CARCINOGENESIS
- Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients
- (2016) Wenwei Hu et al. PATHOLOGY & ONCOLOGY RESEARCH
- Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer
- (2016) M Akimoto et al. Cell Death & Disease
- Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment
- (2016) Miho Akimoto et al. Nature Communications
- Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia
- (2016) Lei Qin et al. Oncotarget
- Tristetraprolin inhibits gastric cancer progression through suppression of IL-33
- (2016) Kaiyuan Deng et al. Scientific Reports
- Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33
- (2016) Iryna Saranchova et al. Scientific Reports
- An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer
- (2015) Charlotte O'Donnell et al. BRITISH JOURNAL OF CANCER
- IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2–ERK1/2 Pathway
- (2015) Xi-Xiang Yu et al. DIGESTIVE DISEASES AND SCIENCES
- IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism
- (2015) Daisaku Yamada et al. HEPATOLOGY
- IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance
- (2015) XIAO-LEI YE et al. ONCOLOGY REPORTS
- IL-33 activates tumor stroma to promote intestinal polyposis
- (2015) Rebecca L. Maywald et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice
- (2015) Kirsten D. Mertz et al. OncoImmunology
- Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells
- (2015) Peng Xiao et al. OncoImmunology
- IL-33/ST2 pathway contributes to metastasis of human colorectal cancer
- (2014) Xuejian Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy
- (2014) Corinne Cayrol et al. CURRENT OPINION IN IMMUNOLOGY
- Global burden of gastric cancer attributable toHelicobacterpylori
- (2014) Martyn Plummer et al. INTERNATIONAL JOURNAL OF CANCER
- Biliary repair and carcinogenesis are mediated by IL-33–dependent cholangiocyte proliferation
- (2014) Jun Li et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+T and NK Cells
- (2014) Xin Gao et al. JOURNAL OF IMMUNOLOGY
- Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity
- (2014) J Y Kim et al. ONCOGENE
- Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value
- (2014) Felix Berlth WORLD JOURNAL OF GASTROENTEROLOGY
- Polarization of ILC2s in Peripheral Blood Might Contribute to Immunosuppressive Microenvironment in Patients with Gastric Cancer
- (2014) Qingli Bie et al. Journal of Immunology Research
- Transgenic expression of IL-33 activates CD8+ T cells and NK cells and inhibits tumor growth and metastasis in mice
- (2013) Kun Gao et al. CANCER LETTERS
- Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells
- (2013) Ivan P. Jovanovic et al. INTERNATIONAL JOURNAL OF CANCER
- The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma
- (2013) Su-Feng Chen et al. JOURNAL OF PATHOLOGY
- Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy
- (2013) Takaki Yoshikawa et al. SURGERY TODAY
- IL-33/ST2 axis in inflammation and immunopathology
- (2012) Marija Milovanovic et al. IMMUNOLOGIC RESEARCH
- Global burden of cancers attributable to infections in 2008: a review and synthetic analysis
- (2012) Catherine de Martel et al. LANCET ONCOLOGY
- Serum Interleukin-33 Levels in Patients with Gastric Cancer
- (2011) Pinghu Sun et al. DIGESTIVE DISEASES AND SCIENCES
- ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma
- (2011) Ivan Jovanovic et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The Gastric Cardia Is Not a Target for Human Papillomavirus-Induced Carcinogenesis
- (2010) J. Koshiol et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The enigmatic processing and secretion of interleukin-33
- (2010) Weihua Zhao et al. Cellular & Molecular Immunology
- In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction
- (2010) N. R. Blatner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1
- (2009) C. Cayrol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TRAF6 is a critical signal transducer in IL-33 signaling pathway
- (2008) Megumi Funakoshi-Tago et al. CELLULAR SIGNALLING
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More